NWY-12806-80260
4 vaccinations
1 coded response
40 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 66+
- ZIP prefix
- 760 / TX
- Registered
- 2021-01-01
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-30
Dose 1 — Moderna
-
2021-01-01
Registered in v-safe
- 2021-01-01
- 2021-01-02
- 2021-01-03
- 2021-01-04
- 2021-01-05
- 2021-01-06
- 2021-01-15
- 2021-01-21
-
2021-01-25
Dose 2 — Moderna
- 2021-01-25
-
2021-01-26
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2021-01-27
- 2021-01-28
- 2021-01-29
- 2021-01-31
- 2021-02-01
- 2021-02-08
- 2021-02-15
- 2021-02-22
- 2021-03-01
- 2021-03-08
- 2021-04-26
-
2021-07-26
Survey response — 6 months, dose 2MedDRA: Biopsy endometrium abnormal, Office visit, Postmenopausal haemorrhage, Uterine dilation and curettage — Feeling: Good · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professionalFree text: Symptoms: Post menopausal bleeding · Healthcare visit (other): Office visit with endometria biopsy. Then outpatient D&CMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-07-26
Report sent to call center — 6 months, dose 2Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
- 2021-08-03
-
2021-08-05
Call successfulParticipant prefers to complete VAERS report online
-
2021-09-20
Dose 3 — Moderna
- 2021-10-23
- 2021-10-25
- 2021-11-01
- 2021-12-20
- 2022-03-23
-
2022-07-14
Dose 4 — Pfizer-BioNTech
- 2022-07-16
- 2022-07-17
- 2022-07-18
- 2022-07-19
- 2022-07-20
- 2022-07-21
- 2022-07-28
- 2022-08-04
- 2022-08-11
- 2022-08-18
- 2022-08-25
- 2022-10-13
- 2023-01-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-30 | Moderna | |
| 2 | 2021-01-25 | Moderna | |
| 3 | 2021-09-20 | Moderna | No |
| 4 | 2022-07-14 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-07-26 | Successful 2021-08-05 |
Participant prefers to complete VAERS report online |
Free text
Release 9 — 6 months, dose 2
Symptoms: Post menopausal bleeding
Healthcare visit (other): Office visit with endometria biopsy. Then outpatient D&C
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Biopsy endometrium | ○ | · | ○ |
| HCVO | Biopsy endometrium abnormal | ✓ | · | ✓ |
| HCVO | Office visit | ✓ | · | ✓ |
| HCVO | Uterine dilation and curettage | ✓ | · | ✓ |
| SD | Postmenopausal haemorrhage | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release